{"type":"trials","record":{"id":41490,"source_id":"clinicaltrials-gov","external_id":"NCT04770545","title":"An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD","brief_summary":"This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment at Month 24 of either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600).","overall_status":"Completed","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Apellis Pharmaceuticals, Inc.","enrollment":792,"countries":["United States","Argentina","Australia","Brazil","Canada","Czechia","France","Germany","Israel","Italy","Netherlands","New Zealand","Poland","Spain","United Kingdom"],"start_date":"2021-03-04","completion_date":"2025-09-05","last_update_date":"2026-06-18","source_url":"https://clinicaltrials.gov/study/NCT04770545","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"GALE","age_range":"60 Years","comparator":null,"organization":"Apellis Pharmaceuticals, Inc.","interventions":["PEGCETACOPLAN (APL-2)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Incidence and severity of ocular and systemic adverse events — Up to 36 Months","Change from baseline in the total area of GA lesion(s) in the study eye (in mm2) — Up to 36 Months","Change from baseline in NL-BCVA score (study eye) — Up to 36 Months","Change from baseline in LL-BCVA score (study eye) — Up to 36 Months"],"design_description":"NON RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Geographic Atrophy Secondary to Age-related Macular Degeneration","PEGCETACOPLAN (APL-2)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04770545","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-03-04 to 2025-09-05","comparator":null,"confidence":"structured-source","population":"ALL · 60 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.821Z","intervention":["PEGCETACOPLAN (APL-2)"],"participants":792,"study_design":"NON RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Incidence and severity of ocular and systemic adverse events — Up to 36 Months","Change from baseline in the total area of GA lesion(s) in the study eye (in mm2) — Up to 36 Months","Change from baseline in NL-BCVA score (study eye) — Up to 36 Months","Change from baseline in LL-BCVA score (study eye) — Up to 36 Months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41490","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}